
Autolus Therapeutics (AUTL) Stock Forecast & Price Target
Autolus Therapeutics (AUTL) Analyst Ratings
Bulls say
Autolus Therapeutics is expected to experience significant growth in the next few years, primarily driven by the growing demand and access for Aucatyzl in both the US and UK markets. The company's clinical-stage pipeline also shows promising potential for the treatment of cancer and autoimmune indications. Additionally, the company's strong financial performance, with $26.2M in revenue generated in 1Q26 and expected revenue of $120-135M in 2026, reveals its capability to drive continued growth. The potential of AUTO-8 in AL amyloidosis and obe-cel in progressive MS, with early data expected in 2026, serves as short-term catalysts, and the company's focus on safety and ease of use of Aucatzyl, as highlighted by KOLs, positions the company for long-term success in the competitive market of CAR-T therapies.
Bears say
Autolus Therapeutics is a platform technology company with a diverse pipeline, but risks to the achievement of our $10 price target include safety concerns with clinical programs, potential for lower than expected efficacy, and stiff competition in the market. Additionally, significant capital will be needed through 2040, and the company's cash runway only extends to 2027, posing a financial risk. The company's success in the pediatric relapse ALL market may provide some opportunities, but risks such as regulatory concerns and risks related to intellectual property also remain.
This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Autolus Therapeutics (AUTL) Analyst Forecast & Price Prediction
Start investing in Autolus Therapeutics (AUTL)
Order type
Buy in
Order amount
Est. shares
0 shares